CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

apomorphine hydrochloride

Last Updated: April 22, 2021
Result type: Reports
Project Number: SR0650-000
Product Line: Reimbursement Review

Generic Name: apomorphine hydrochloride

Brand Name: Kynmobi

Manufacturer: Sunovion Pharmaceuticals Canada Inc.

Therapeutic Area: Parkinson’s disease

Indications: ​Indicated for the acute, intermittent treatment of “OFF” episodes in patients with Parkinson's disease.

Manufacturer Requested Reimbursement Criteria1: Indicated for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Date Recommendation Issued: February 24, 2021

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input open May 29, 2020
Call for patient input closed July 20, 2020
Clarification:

- Patient input submission received from The Michael J. Fox Foundation for Parkinson's Research, Parkinson Association of Alberta, Parkinson Canada, Parkinson Quebec and Parkinson Society BC (PSBC)

Submission received June 25, 2020
Clarification:

Submission was previously withdrawn and has been refiled by the sponsor

 

Submission accepted July 10, 2020
Review initiated July 13, 2020
Draft CADTH review report(s) provided to sponsor for comment August 28, 2020
Deadline for sponsors comments September 09, 2020
CADTH responses on draft review report(s) provided to sponsor October 08, 2020
Expert committee meeting (initial) October 21, 2020
Draft recommendation issued to sponsor November 04, 2020
End of embargo period November 18, 2020
Clarification:

- Reconsideration requested

Expert committee meeting February 17, 2021
Final recommendation issued to sponsor and drug plans February 24, 2021
Final recommendation posted February 26, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) March 10, 2021
CADTH review report(s) posted -